SYK vs RMD stock comparison
Stryker vs. Resmed · data as of November 13, 2026
Stryker (SYK) has a market value of about $117.9B, Resmed (RMD) about $33.7B. Over their latest twelve months Stryker had revenue of $26.3B and Resmed $5.7B.
On our five checks Resmed scores higher: 4.2 out of 5 (excellent) against 2.8 (average).
By area, the stronger company is Resmed on value; Resmed on track record; Resmed on financial health.
Resmed is cheaper on earnings (P/E 21.8 vs. 33.0).
Stryker leads on 6 of the compared lines and Resmed on 17.
Side by side
| SYK | RMD | |
|---|---|---|
| Size and price | ||
| Market cap | $117.9B | $33.7B |
| Share price | $309.64 | $239.53 |
| Score | ||
| Overall score (of 5) | 2.8 | 4.2 |
| Value | 0 | 3 |
| Future growth | 4 | 4 |
| Track record | 3 | 5 |
| Financial health | 3 | 5 |
| Shareholder returns | 4 | 4 |
| Valuation | ||
| P/E (TTM) | 33.0 | 21.8 |
| Forward P/E | 18.9 | 18.9 |
| Price / free cash flow | 25.8 | 20.9 |
| Price / sales | 4.5 | 5.9 |
| EV / EBITDA | 18.5 | 15.9 |
| PEG | 2.22 | 0.83 |
| DCF value vs. price | −38% | −28% |
| Business | ||
| Revenue | $26.3B | $5.7B |
| Net income | $3.6B | $1.6B |
| Free cash flow | $4.6B | $1.6B |
| Net margin | 13.8% | 27.8% |
| Gross margin (5-yr avg.) | 63.7% | 57.9% |
| ROIC (5-yr avg.) | 9.0% | 18.9% |
| Growth | ||
| Revenue growth (1 yr) | 11.2% | 9.8% |
| Revenue growth (5 yrs, per year) | 11.8% | 12.1% |
| EPS growth (5 yrs, per year) | 14.9% | 26.3% |
| Balance sheet and payouts | ||
| Net cash (cash minus debt) | -$12.2B | $400M |
| Dividend yield | 1.14% | 1.10% |
| Shareholder yield | 1.1% | 3.2% |
| Analysts | ||
| Upside to average target | +10% | +10% |
| Consensus rating | Buy | Buy |
Highlighted = the better figure on that line. Revenue, net income and free cash flow: SYK TTM to September 30, 2026, RMD TTM to September 30, 2026. Not investment advice.
Frequently asked questions
Which is the better stock, Stryker or Resmed?
We do not give buy or sell advice. On our five checks (value, growth, track record, financial health and shareholder returns) Resmed scores 4.2 out of 5 and Stryker 2.8; the table shows where each one is stronger.
Is Stryker cheaper than Resmed?
On trailing earnings, Resmed trades at a P/E of 21.8 and Stryker at 33.0, so Resmed is cheaper by this measure. A lower P/E can also reflect slower expected growth.
Which grows faster, Stryker or Resmed?
Over five years Resmed grew revenue about 12.1% a year and Stryker about 11.8% a year.
Which pays a higher dividend?
Stryker yields 1.14% and Resmed 1.10%.
Full Stryker analysis → Full Resmed analysis →
More comparisons
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.